Registry of Lobbyists

Registration - In-house Corporation

Apotex Inc. / Jeff Watson, President

Registration Information

In-house Corporation name: Apotex Inc.
Previous in-house corporation names
Responsible Officer Name: Jeff Watson, President 
Responsible Officer Change History
Initial registration start date: 1996-06-26
Registration status: Inactive
Registration Number: 938533-452

Associated Communications

Total Number of Communication Reports: 39

Monthly communication reports in the last 6 months: 0

Version 12 of 29 (2007-01-19 to 2007-07-16)

Version 12 of 29 (2007-01-19 to 2007-07-16) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Apotex Inc.
150 Signet Drive
Toronto, ON  M9L 1T9
Canada
Telephone number: 416-749-9300
Fax number: 416-749-9578  
Responsible officer name and position during the period of this registration: JACK KAY, PRESIDENT & COO  
Description of activities: Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 260 medicines to the healthcare system and exports these to 115 countries. Apotex's 2005 Research and Development (R&D) budget was $183 million - positioning it in the top 15 companies for all industrial sectors (20% of sales).
 
Parent: The corporation is not a subsidiary of any other parent corporations.
Coalition The corporation is not a member of a coalition.
Subsidiary: ACCUCAPS INDUSTRIES LIMITED
2125 AMBASSADOR DRIVE
WINDSOR, ON
Canada N9C 3R5

APOPHARMA INC.
200 BARMAC DRIVE
TORONTO, ON
Canada M9L 2Z7

APOTEX FERMENTATION INC.
50 SCURFIELD BOULEVARD
WINNIPEG, MB
Canada R3Y 1G4

APOTEX PHARMACHEM INC.
34 SPALDING DRIVE
BRANTFORD, ON
Canada N9C 3R5

STARPLEX SCIENTIFIC
50 STEINWAY BOULEVARD
ETOBICOKE, ON
Canada M8W 6Y3

Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: ELIE BETITO
Position title: Director, Public & Government Affairs
Public offices held: No
 
Name: BARRY SHERMAN
Position title: CHAIRMAN & CEO
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Canadian Heritage (PCH), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Revenue Canada (RC), Solicitor General Canada (SGC), Treasury Board Of Canada Secretariat (TBS)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Government Procurement, Health, Industry, International Trade, Justice and Law Enforcement, Science and Technology, Taxation and Finance
 
Subject Matter: Retrospective: Notice of Compliance (NOC) Regulations; Drug Review and Approvals; World Trade Organization (WTO) Trade Discussions
Subject Matter: Prospective: Lobbying on changes to Notice of Compliance Regulations (NOC); National Pharmacare; AIDS Drugs for Africa; Generic Drug Approvals; WTO Trade Discussions
 

Details Regarding the Identified Subject Matter

Categories Description
Legislative Proposal Changes to NOC Regulations
Policy or Program Drug Approvals/Review
Regulation Patent Regulations




Date Modified: